Prospective, Multicentre, Open-label, Single-arm, Non-interventional Regulatory Post-marketing Surveillance(rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda® (Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea

Registration

Registration

NCT03560336

Study type

OBSERVATIONAL

Status

COMPLETED

Enrollment

758

Start

2018-07-05

Primary completion

2020-12-02

Lead sponsor

Novo Nordisk A/S

Conditions

Obesity; Overweight

Interventions

DRUG:Liraglutide

Results posted

FALSE

Individual participant data sharing

YES

Secondary identifiers

OTHER:U111-1199-8606

Registered primary outcomes

• Incidence of adverse events (AEs) by preferred term (PT) [From baseline to week 13 (± 3 weeks)]
• Incidence of adverse events (AEs) by preferred term (PT) [From baseline to week 26 (± 3 weeks)]